Schilke Tobin
Visual SEC Form 4 history across 2 companies, 12 transactions and 6 filings.
Open-market buy performance
90-day forward return on this insider's open-market purchases
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Monthly open-market activity
Reported purchase and sale transaction counts
Net value flow
Buys minus sells
Transaction texture
Ownership and ticket size
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
No latest transaction fact is available.
No open-market insider purchase is available.
No open-market insider sale is available.
Associated companies
Visual map of known reporting history
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| RVNC | Schilke Tobin | CFO | grant | 1.00k | $218k | A | — | 01/03/2025 | 12/31/2024 | |
| RVNC | Schilke Tobin | CFO | grant | 434 | $324k | A | — | 01/03/2024 | 12/31/2023 |
Schilke Tobin Insider Activity FAQ
SEC Form 4 context
Who is Schilke Tobin?
Schilke Tobin is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001678984.
Which companies has Schilke Tobin reported transactions for?
Crinetics Pharmaceuticals, Inc., Revance Therapeutics, Inc.
When was Schilke Tobin's latest insider buy?
No open-market insider purchase is available for this period.
When was Schilke Tobin's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.